FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044804952> ?p ?o ?g. }

• W2044804952 endingPage "1455" @default.
• W2044804952 startingPage "1446" @default.
• W2044804952 abstract "Objective: This analysis assessed the incidence, severity, onset, and duration of nausea among patients with major depressive disorder (MDD) treated with the new antidepressant duloxetine. Methods: Data were pooled from 8 double-blind, randomized, placebo- and active comparator-controlled trials employing patients with MDD that were submitted to the US Food and Drug Administration to support duloxetine's new drug application for treatment of MDD. Results: The numbers of patients receiving each regimen were as follows: placebo, n = 777; duloxetine 40 mg/d, n = 177; duloxetine 60 mg/d, n = 251; duloxetine 80 mg/d, n = 363; duloxetine 120 mg/d, n = 348; paroxetine 20 mg/d, n = 359; and fluoxetine 20 mg/d, n = 70. In acute placebo-controlled trials of duloxetine 40 to 120 mg/d, treatment-emergent nausea was reported by more duloxetine-treated patients than those receiving placebo (19.9% [227/1139] vs 6.9% [l54/777], respectively; P <). Among duloxetine-treated patients, the median time to onset of nausea was 1 day, and the median duration of nausea was 7 days. The incidence of nausea was similar to placebo rates after 1 week. In paroxetine-controlled studies, the incidence of treatment-emergent nausea in patients receiving duloxetine did not differ significantly from paroxetine (14.4% vs 12.0%, respectively). In head-to-head studies, the incidence of treatment-emergent nausea with duloxetine did not differ significantly from that with fluoxetine (17.1% vs 15.7%, respectively). Most duloxetine-treated patients reported nausea to be mild (52.9%) or moderate (41.4%). Treatment discontinuation secondary to nausea occurred in more duloxetine-treated patients than those receiving placebo (1.4% [16/1139] vs 0.1% [1/777], respectively;P = 0.002). Following abrupt discontinuation after acute treatment, 5.9% of duloxetine-treated patients exhibited nausea compared with 0.3% of patients receiving placebo (P < 0.001). The incidence of treatment-emergent nausea during 6-month continuation of duloxetine treatment (80 mg/d, 2.1%; 120 mg/d, 1.3%) was similar to placebo (1.6%). Following abrupt discontinuation after 8 months of treatment, nausea was reported by 1.6% of patients receiving duloxetine 120 mg/d compared with 0% for those receiving duloxetine 80 mg/d and 0% for placebo. Conclusions: Duloxetine induced mild to moderate nausea in a subset of patients with MDD during treatment initiation. Nausea resolved rapidly with continued treatment. The incidence of duloxetine-induced nausea resembled that produced by paroxetine and fluoxetine." @default.
• W2044804952 created "2016-06-24" @default.
• W2044804952 creator A5010720683 @default.
• W2044804952 creator A5042304299 @default.
• W2044804952 creator A5061204435 @default.
• W2044804952 creator A5063618224 @default.
• W2044804952 creator A5064151665 @default.
• W2044804952 date "2004-09-01" @default.
• W2044804952 modified "2023-10-09" @default.
• W2044804952 title "Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine" @default.
• W2044804952 cites W163472623 @default.
• W2044804952 cites W1969114608 @default.
• W2044804952 cites W1971393265 @default.
• W2044804952 cites W1974584667 @default.
• W2044804952 cites W1979917573 @default.
• W2044804952 cites W1980533538 @default.
• W2044804952 cites W1982721912 @default.
• W2044804952 cites W1982892378 @default.
• W2044804952 cites W1993072085 @default.
• W2044804952 cites W1993769419 @default.
• W2044804952 cites W2001233081 @default.
• W2044804952 cites W2003363634 @default.
• W2044804952 cites W2018425549 @default.
• W2044804952 cites W2021817727 @default.
• W2044804952 cites W2033192117 @default.
• W2044804952 cites W2034112753 @default.
• W2044804952 cites W2044259586 @default.
• W2044804952 cites W2061271938 @default.
• W2044804952 cites W2069090735 @default.
• W2044804952 cites W2075555377 @default.
• W2044804952 cites W2080989089 @default.
• W2044804952 cites W2103553382 @default.
• W2044804952 cites W2116547795 @default.
• W2044804952 cites W2124733814 @default.
• W2044804952 cites W2125265485 @default.
• W2044804952 cites W2159011576 @default.
• W2044804952 cites W2162060590 @default.
• W2044804952 cites W2164907650 @default.
• W2044804952 cites W2197995441 @default.
• W2044804952 cites W2245189293 @default.
• W2044804952 cites W2341319633 @default.
• W2044804952 cites W2407115578 @default.
• W2044804952 cites W2418831554 @default.
• W2044804952 cites W2506210560 @default.
• W2044804952 cites W72273208 @default.
• W2044804952 doi "https://doi.org/10.1016/j.clinthera.2004.09.010" @default.
• W2044804952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15531007" @default.
• W2044804952 hasPublicationYear "2004" @default.
• W2044804952 type Work @default.
• W2044804952 sameAs 2044804952 @default.
• W2044804952 citedByCount "63" @default.
• W2044804952 countsByYear W20448049522012 @default.
• W2044804952 countsByYear W20448049522014 @default.
• W2044804952 countsByYear W20448049522015 @default.
• W2044804952 countsByYear W20448049522016 @default.
• W2044804952 countsByYear W20448049522018 @default.
• W2044804952 countsByYear W20448049522020 @default.
• W2044804952 countsByYear W20448049522021 @default.
• W2044804952 countsByYear W20448049522022 @default.
• W2044804952 crossrefType "journal-article" @default.
• W2044804952 hasAuthorship W2044804952A5010720683 @default.
• W2044804952 hasAuthorship W2044804952A5042304299 @default.
• W2044804952 hasAuthorship W2044804952A5061204435 @default.
• W2044804952 hasAuthorship W2044804952A5063618224 @default.
• W2044804952 hasAuthorship W2044804952A5064151665 @default.
• W2044804952 hasConcept C120665830 @default.
• W2044804952 hasConcept C121332964 @default.
• W2044804952 hasConcept C126322002 @default.
• W2044804952 hasConcept C142724271 @default.
• W2044804952 hasConcept C170493617 @default.
• W2044804952 hasConcept C204787440 @default.
• W2044804952 hasConcept C27081682 @default.
• W2044804952 hasConcept C2775864247 @default.
• W2044804952 hasConcept C2776134451 @default.
• W2044804952 hasConcept C2777828372 @default.
• W2044804952 hasConcept C2779144063 @default.
• W2044804952 hasConcept C2779177272 @default.
• W2044804952 hasConcept C2780051608 @default.
• W2044804952 hasConcept C2780580376 @default.
• W2044804952 hasConcept C2780764818 @default.
• W2044804952 hasConcept C2781161787 @default.
• W2044804952 hasConcept C2910564767 @default.
• W2044804952 hasConcept C31487548 @default.
• W2044804952 hasConcept C42219234 @default.
• W2044804952 hasConcept C61511704 @default.
• W2044804952 hasConcept C71924100 @default.
• W2044804952 hasConceptScore W2044804952C120665830 @default.
• W2044804952 hasConceptScore W2044804952C121332964 @default.
• W2044804952 hasConceptScore W2044804952C126322002 @default.
• W2044804952 hasConceptScore W2044804952C142724271 @default.
• W2044804952 hasConceptScore W2044804952C170493617 @default.
• W2044804952 hasConceptScore W2044804952C204787440 @default.
• W2044804952 hasConceptScore W2044804952C27081682 @default.
• W2044804952 hasConceptScore W2044804952C2775864247 @default.
• W2044804952 hasConceptScore W2044804952C2776134451 @default.
• W2044804952 hasConceptScore W2044804952C2777828372 @default.
• W2044804952 hasConceptScore W2044804952C2779144063 @default.
• W2044804952 hasConceptScore W2044804952C2779177272 @default.

• next